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Introduction: No controlled clinical trials had studied the role of maraviroc (MRV) in fully suppressed patients [1].
Methods and Materials: MRV-cohort is an observational, retrospective, multicentric (27 sites) large cohort study of patients
starting MRV in clinical practice under different circumstances, with at least 48 weeks of follow-up. For the present analysis we
selected all those patients starting with an HIV-RNAB50 copies/mL. Demographics, baseline CD4 cell count, past history of
antiretroviral treatment (ART), tropism, reasons for MRV use, MRV based therapy and change/end of MRV use were assessed.
Paired analysis of lipid, hepatic and kidney profile changes and univariate and multivariate analyses of HIV-RNAB50 copies/mL
at 48 weeks were explored.
Results: We included 247 out of 667 subjects from the entire cohort. At study entry, their median age was 47 years, 23% were
women, 31% MSM, 49% had CDC category C, median CD4 counts were 468 cells/mm3, 46% were HCV and 4.5% AgHBs.
Tropism information was available in 197 (94% R5). Median length of prior ARTV was 10.7 years, with exposure to a median of
three drug families. Main reasons for prescribing MRV were: toxicity 38%, inmunodiscordance 23%, simplification 19% and
admission in a clinical trial 10.4%. MRV based therapies used were MRV2NRTIs 9%, MRVPI 46%, MRVPIother 40% and
MRVother 5%. At 48 weeks, 23% of patients had changed or finished MRV therapy due to toxicity 2.4%, virological failure 2%,
immunological failure 1.2%, simplification 3,2%, trial requirement 9.7%, medical decision 2.8%, treatment suspension 1.2% and
unknown 0.4%. At 48 weeks, no significant changes were observed in lipid, hepatic or kidney profiles, and 85% of patients
remained with HIV-RNAB50 copies/mL. Focusing on viral response univariate and multivariate models did not show any
significant baseline variable explaining viral failure.
Conclusions: In clinical practice MRV was used, mostly in R5 positive patients, with adequate efficacy and tolerance, but
important number of patients changed due to non-clinical reasons. In this scenario neither reason for use of MRV nor MRV-
based therapy explained viral failure.
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